Lee G. Wilke, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Lee Wilke specializes in benign and malignant diseases of the breast; sentinel lymph-node mapping; neoadjuvant therapy for breast cancer; nipple-sparing breast surgery and minimally invasive surgery of the breast.
Dr. Wilke earned her medical degree from Duke University in Durham, N.C., and completed her residency and a research fellowship at the University of Michigan in Ann Arbor, Mich. She is certified by the American Board of Surgery and is the Director of the UW Health Breast Center.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Surgery|
Professional Certifications and Education
ACS Resident Research Fellow in Immunotherapy, University of Michigan Hospitals, Ann Arbor, MI 1996-1998
University of Michigan Hospitals, Ann Arbor, MI, MI
University of Michigan Hospitals, Ann Arbor, MI, MI
Duke University School of Medicine, Durham, NC, 1993
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Programs & Conditions
- Breast Cancer
- Breast Center
Dr. Wilke’s main research interest are clinical trials that seek novel methods of treating breast cancer. She is a member of the executive committee of the American College of Surgeons Oncology Group, and also is a collaborator and investigator evaluating the use of optical spectroscopy to evaluate breast tumor margins and aid in the diagnosis and evaluation of solid tumors.
Van Zee KJ Hansen NM Barrio AV Connor CS Danforth DN Euhus DM Kulkarni SA McCready DR McLaughlin S Wilke LG .
Commentary on the canadian national breast screening study. Ann Surg Oncol. 2014 Dec;21(13):4397-8
[PubMed ID: 24859935]
Wilke LG Czechura T Wang C Lapin B Liederbach E Winchester DP Yao K .
Repeat Surgery After Breast Conservation for the Treatment of Stage 0 to II Breast Carcinoma: A Report From the National Cancer Data Base, 2004-2010. JAMA Surg. 2014 Nov 12;
[PubMed ID: 25390819]
Boughey JC McCall LM Ballman KV Mittendorf EA Ahrendt GM Wilke LG Taback B Leitch AM Flippo-Morton T Hunt KK .
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014 Oct;260(4):608-14; discussion 614-6
[PubMed ID: 25203877]
Mirrielees JA Kapur JH Szalkucki LM Harter JM Salkowski LR Strigel RM Traynor AM Wilke LG .
Metastasis of primary lung carcinoma to the breast: a systematic review of the literature. J Surg Res. 2014 May 15;188(2):419-31
[PubMed ID: 24560348]
Zasadil LM Andersen KA Yeum D Rocque GB Wilke LG Tevaarwerk AJ Raines RT Burkard ME Weaver BA .
Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014 Mar 26;6(229):229ra43
[PubMed ID: 24670687]
Hornsby WE Douglas PS West MJ Kenjale AA Lane AR Schwitzer ER Ray KA Herndon JE 2nd Coan A Gutierrez A Hornsby KP Hamilton E Wilke LG Kimmick GG Peppercorn JM Jones LW .
Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. Acta Oncol. 2014 Jan;53(1):65-74
[PubMed ID: 23957716]
Caretta-Weyer H Greenberg CG Wilke LG Weiss J LoConte NK Decker M Steffens NM Smith MA Neuman HB .
Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis. Ann Surg Oncol. 2013 Dec;20(13):4145-52
[PubMed ID: 23959051]
Boughey JC Suman VJ Mittendorf EA Ahrendt GM Wilke LG Taback B Leitch AM Kuerer HM Bowling M Flippo-Morton TS Byrd DR Ollila DW Julian TB McLaughlin SA McCall L Symmans WF Le-Petross HT Haffty BG Buchholz TA Nelson H Hunt KK .
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 9;310(14):1455-61
[PubMed ID: 24101169]
Jones LW Fels DR West M Allen JD Broadwater G Barry WT Wilke LG Masko E Douglas PS Dash RC Povsic TJ Peppercorn J Marcom PK Blackwell KL Kimmick G Turkington TG Dewhirst MW .
Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila). 2013 Sep;6(9):925-37
[PubMed ID: 23842792]
Brown JQ Bydlon TM Kennedy SA Caldwell ML Gallagher JE Junker M Wilke LG Barry WT Geradts J Ramanujam N .
Optical spectral surveillance of breast tissue landscapes for detection of residual disease in breast tumor margins. PLoS One. 2013;8(7):e69906
[PubMed ID: 23922850]
Esbona K Li Z Wilke LG .
Intraoperative imprint cytology and frozen section pathology for margin assessment in breast conservation surgery: a systematic review. Ann Surg Oncol. 2012 Oct;19(10):3236-45
[PubMed ID: 22847119]
Caretta-Weyer H Sisney GA Beckman C Burnside ES Salkowsi LR Strigel RM Wilke LG Neuman HB .
Impact of axillary ultrasound and core needle biopsy on the utility of intraoperative frozen section analysis and treatment decision making in women with invasive breast cancer. Am J Surg. 2012 Sep;204(3):308-14
[PubMed ID: 22483606]
Cuneo KC Dash RC Wilke LG Horton JK Koontz BF .
Risk of invasive breast cancer and ductal carcinoma in situ in women with atypical papillary lesions of the breast. Breast J. 2012 Sep;18(5):475-8
[PubMed ID: 22776070]
Decker MR Greenblatt DY Havlena J Wilke LG Greenberg CC Neuman HB .
Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery. 2012 Sep;152(3):382-8
[PubMed ID: 22739071]
Ibarra-Drendall C Troch MM Barry WT Broadwater G Petricoin EF 3rd Wulfkuhle J Liotta LA Lem S Baker JC Jr Ford AC Wilke LG Zalles C Kuderer NM Hoffman AW Shivraj M Mehta P Williams J Tolbert N Lee LW Pilie PG Yu D Seewaldt VL .
Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat. 2012 Apr;132(2):487-98
[PubMed ID: 21647677]
Bydlon TM Barry WT Kennedy SA Brown JQ Gallagher JE Wilke LG Geradts J Ramanujam N .
Advancing optical imaging for breast margin assessment: an analysis of excisional time, cautery, and patent blue dye on underlying sources of contrast. PLoS One. 2012;7(12):e51418
[PubMed ID: 23251526]
Latosinsky S Cheifetz RE Wilke LG .
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Am Coll Surg. 2011 Sep;213(3):447-50
[PubMed ID: 21871383]
Pilie PG Ibarra-Drendall C Troch MM Broadwater G Barry WT Petricoin EF 3rd Wulfkuhle JD Liotta LA Lem S Baker JC Jr Stouder A Ford AC Wilke LG Zalles CM Mehta P Williams J Shivraj M Su Z Geradts J Yu D Seewaldt VL .
Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):476-82
[PubMed ID: 21242333]
Clifford EJ De Vol EB Pockaj BA Wilke LG Boughey JC .
Early results from a novel quality outcomes program: the American Society Of Breast Surgeons' Mastery of Breast Surgery. Ann Surg Oncol. 2010 Oct;17 Suppl 3:233-41
[PubMed ID: 20853039]
Wilke LG Ballman KV McCall LM Giuliano AE Whitworth PW Blumencranz PW Reintgen DS Burak WE Leitch AM Hunt KK .
Adherence to the National Quality Forum (NQF) breast cancer measures within cancer clinical trials: a review from ACOSOG Z0010. Ann Surg Oncol. 2010 Aug;17(8):1989-94
[PubMed ID: 20309640]